Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial)

Trial Profile

Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms OLGA
  • Most Recent Events

    • 08 Nov 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 02 May 2013 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 09 Mar 2013 New source identified and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top